Australian Pharmaceutical Industries Ltd
ASX:API
Intrinsic Value
Australian Pharmaceutical Industries Ltd. engages in the wholesale, product delivery, retail services, marketing programs and business advisory services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of API.
Australian Pharmaceutical Industries Ltd's market capitalization is 753.8m AUD.
API stock price is 1.53 AUD.
API.
API. Open DCF Valuation
API. Open Relative Valuation
API's ROIC (Return on Invested Capital) has decreased in the last 3 years from 1% to 0%.
API has positive Free Cash Flow for the last twelve months.
API has positive Gross Profit for the last twelve months.
API's ROE (Return on Equity) has increased in the last 3 years from -3% to 0%.
API's short-term assets (990m AUD) exceed its short-term liabilties (825m AUD).
API has positive three-year average ROE (Return on Equity): 7%. The company is efficient at transforming stockholders' equity into net income.
API's long-term assets (2B AUD) exceed its long-term liabilties (1B AUD).
API's ROE (Return on Equity) for the past 12 months is very low and is equal to 0%.
API's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 0%.
API has positive Operating Income for the last twelve months.
API has positive Net Income for the last twelve months.
API has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
API's Revenue has dropped by 34% over the past 12 months.
API's Altman Z-Score is very high and is equal to 3.01.
API's D/E (Debt to Equity) is very low and is equal to 0.61.
API has positive Net Debt. This means that the company has more debt (268m AUD) than cash and short-term investments (39m AUD).
API doesn't generate enough operating income (24m AUD) to safely cover interest payments on its debt (-10m AUD).
Fundamental Analysis
Australian Pharmaceutical Industries Ltd
Balance Sheet Decomposition
Australian Pharmaceutical Industries Ltd
| Current Assets | 989.8m |
| Cash & Short-Term Investments | 38.8m |
| Receivables | 589.1m |
| Other Current Assets | 361.9m |
| Non-Current Assets | 540.2m |
| Long-Term Investments | 2.4m |
| PP&E | 230.8m |
| Intangibles | 126.5m |
| Other Non-Current Assets | 180.5m |
| Current Liabilities | 825.5m |
| Accrued Liabilities | 27.2m |
| Short-Term Debt | 20.9m |
| Other Current Liabilities | 777.4m |
| Non-Current Liabilities | 265.7m |
| Long-Term Debt | 246.9m |
| Other Non-Current Liabilities | 18.8m |
Earnings Waterfall
Australian Pharmaceutical Industries Ltd
|
Revenue
|
4B
AUD
|
|
Cost of Revenue
|
-3.5B
AUD
|
|
Gross Profit
|
496.6m
AUD
|
|
Operating Expenses
|
-472.7m
AUD
|
|
Operating Income
|
23.9m
AUD
|
|
Other Expenses
|
-22.5m
AUD
|
|
Net Income
|
1.4m
AUD
|
Free Cash Flow Analysis
Australian Pharmaceutical Industries Ltd
API Profitability Score
Profitability Due Diligence
Australian Pharmaceutical Industries Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Australian Pharmaceutical Industries Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
API Solvency Score
Solvency Due Diligence
Australian Pharmaceutical Industries Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Australian Pharmaceutical Industries Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
API Price Targets Summary
Australian Pharmaceutical Industries Ltd
According to Wall Street analysts, the average 1-year price target for
API
is 1.53 AUD
.
Shareholder Return
API Price
Australian Pharmaceutical Industries Ltd
| Average Annual Return | -4.01% |
| Standard Deviation of Annual Returns | 0.91% |
| Max Drawdown | -30% |
| Market Capitalization | 753.8m AUD |
| Shares Outstanding | 492 656 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Australian Pharmaceutical Industries Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Australian Pharmaceutical Industries Ltd. engages in the wholesale, product delivery, retail services, marketing programs and business advisory services. The company is headquartered in Melbourne, Victoria. The Company’s segments include Australia and New Zealand. The Australia segment is engaged in distribution of pharmaceutical, medical, health, beauty and lifestyle products and retail services to pharmacies, the purchase and sale of health, beauty and lifestyle products and services within the retail industry, including cosmetic products and non-invasive procedures. The New Zealand segment manufactures and owns rights for pharmaceutical medicines and consumer toiletries. The firm's brands include Priceline & Priceline Pharmacy, which is a health, beauty and wellbeing retailer; Soul Pattinson Chemist, which is a pharmacy brand; Pharmacist Advice, which offers professional service and advice; Club Premium, which is a club for independent pharmacies, and Pharmacy Best Buys, which offers a catalog program.
You don't have any saved screeners yet
